Conditions: Major Depressive Disorder
Keywords: Depression
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 131
Healthy volunteers: no

Brief summary:
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.

Detailed description:
A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, parallel Group Study to Assess the Efficacy and Safety of AZD2066 after 6 weeks of treatment in Patients with Major Depressive Disorder - D0475C00020.

Arms:
arm 1: None arm 2: None arm 3: Duloxetine

Interventions: intervention 1: AZD2066 intervention 2: Placebo intervention 3: Duloxetine
Intervention descriptions: intervention 1: 18 mg once daily intervention 2: None intervention 3: 60 mg once daily

Protocol document: